**Correction to: Mol Cancer**

**https://doi.org/10.1186/s12943-018-0779-z**

Following publication of the original article \[[@CR1]\], the authors reported an error in Table [1](#Tab1){ref-type="table"}. Incorrect value was placed under Efficacy (column), R/R non-GCB DLBCL (row).The value 92% was captured instead of 35%. Corrected table is shown below. The authors would like to apologize for this error.Table 1Clinical trials with BTK inhibitors in B cell malignanciesPatient populationTherapeutic regimenPhaseEfficacyRefR/R CLLIbrutinibIb/IIORR (71%), PR (20%)\[11\]R/R CLLIbrutinibIIIORR (63%)\[248\]TN CLLIbrutinibIb/IIORR (85%), CR (26%)\[199\]TN CLLIbrutinibIIIORR (86%), CR (4%)\[13\]R/R MCLIbrutinibIIORR (68%), CR (21%)\[187\]R/R MCLIbrutinibIIIORR (72%), CR (19%)\[249\]R/R WMIbrutinibIIORR (91%), Major response (73%)\[188\]R/R ABC-DLBCLIbrutinibIIORR (37%)\[196\]R/R CLLIbrutinib-RituximabIIORR (95%), CR (8%)\[250\]R/R CLLIbrutinib-bendamustine-rituximabIIIORR (83%), CR (10%)\[251\]R/R MCLIbrutinib-RituximabIIORR (88%), CR (44%), PR (44%)\[252\]R/R CLLAcalabrutinibI/IIORR (95%)\[12\]R/RAcalabrutinibIIORR (81%), CR (40%), PR (41%)\[219\]R/R CLLONO/GS-4059IORR (96%)\[222\]R/R MCLONO/GS-4059IORR (92%)\[222\]R/R non-GCB DLBCLONO/GS-4059IORR (35%)\[222\]R/R CLLBGB-3111IORR (90%)\[221, 253\]R/R MCLBGB-3111IORR (80%)\[253\]R/R MZLIbrutinibIIORR (51%)\[254\]R/R FLIbrutinibIORR (38%)\[186\]*CLL* Chronic Lymphocytic leukemia, *MCL* Mantle cell lymphoma, *WM* Waldenström's Macroglobulinemia, *ABC-DLBCL* Activated B-cell Diffuse large B cell Lymphoma, *MZL* Marginal zone lymphoma, *FL* Follicular lymphoma, *R/R* relapsed or refractory, *TN* treatment-naïve, *ORR* overall response rate, *CR* complete response, *PR* partial response, Major response: complete response or at least 50% reduction in serum IgM levels
